论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
Authors Wang L
Received 26 January 2022
Accepted for publication 18 May 2022
Published 25 May 2022 Volume 2022:16 Pages 1547—1559
DOI https://doi.org/10.2147/DDDT.S358989
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tin Wui Wong
Abstract: Improving type 2 diabetes using incretin analogues is becoming increasingly plausible. Currently, tirzepatide is the most promising listed incretin analogue. Here, I briefly explain the evolution of drugs of this kind, analyze the residue discrepancies between tirzepatide and endogenous incretins, summarize some existing strategies for prolonging half-life, and present suggestions for future research, mainly involving biased functions. This review aims to present some useful information for designing a dual glucagon like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor agonist.
Keywords: tirzepatide, GLP-1, GIP, Aib, structure–activity relationship, structure–function relationship